Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Abiomed, Inc.    ABMD

ABIOMED, INC.

(ABMD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/30/2020 07/31/2020 08/03/2020 08/04/2020 08/05/2020 Date
298.91(c) 299.94(c) 308.35(c) 305.35(c) 317 Last
277 300 282 274 372 670 372 272 466 674 Volume
-0.06% +0.34% +2.80% -0.97% +3.82% Change
More quotes
Financials (USD)
Sales 2021 813 M - -
Net income 2021 148 M - -
Net cash position 2021 610 M - -
P/E ratio 2021 92,4x
Yield 2021 -
Sales 2022 980 M - -
Net income 2022 217 M - -
Net cash position 2022 878 M - -
P/E ratio 2022 65,1x
Yield 2022 -
Capitalization 13 754 M 13 754 M -
EV / Sales 2021 16,2x
EV / Sales 2022 13,1x
Nbr of Employees 1 536
Free-Float 92,4%
More Financials
Company
Abiomed, Inc. specializes in the development, manufacturing and marketing of medical devices to assist or replace the pumping function of the failing heart. Net sales break down by activity as follows: - product sales (96.4%): heart pumps (Impella brand); - service provision (3.6%): including preventive maintenance services. The United States account for 86.4% of net sales.  
More about the company
Surperformance© ratings of Abiomed, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ABIOMED, INC.
08/04ABIOMED : FDA grants emergency use for heart pump in COVID-19 cases
AQ
08/04ABIOMED : FDA Issues Emergency Use Authorization for Impella Heart Pumps to Prov..
BU
07/31ABIOMED : Large Multi-Center Study in Japan Finds High Survival Rates with Use o..
AQ
07/30ABIOMED : Large Multi-Center Study in Japan Finds High Survival Rates with Use o..
BU
07/16ABIOMED : First Quarter Fiscal 2021 Earnings and Conference Call Notification
BU
07/16ABIOMED : FDA Approves Data Streaming from the Impella Console, Setting the Stag..
BU
07/02ABIOMED : Study Finds 84% Survival Rate in Patients in Cardiogenic Shock and Oth..
AQ
07/01ABIOMED : Study Finds 84% Survival Rate in Patients in Cardiogenic Shock and Oth..
BU
06/16ABIOMED : Appoints New Chief Medical Officer Charles Simonton, M.D
AQ
06/16ABIOMED : Launches Virtual Physician Education Program, CAMP PCI, to Improve Hig..
BU
06/15ABIOMED : Appoints New Chief Medical Officer Charles Simonton, M.D.
BU
06/08ABIOMED : FDA Approves Abiomed's First-in-Human Trial of Impella ECP, World's Sm..
AQ
06/05ABIOMED : FDA Approves Abiomed's First-in-Human Trial of Impella ECP, World's Sm..
BU
06/03ABIOMED : to Hold Fireside Chat at the William Blair 40th Annual Growth Stock Co..
BU
06/02ABIOMED : FDA Issues Emergency Use Authorization for Impella RP as Therapy for C..
AQ
More news
News in other languages on ABIOMED, INC.
08/04ABIOMED : FDA grants emergency use for heart pump in COVID-19 cases
08/04ABIOMED : FDA Issues Emergency Use Authorization for Impella Heart Pumps to Prov..
08/03ABIOMED : Große Multicenter-Studie in Japan findet hohe Überlebensraten bei Verw..
07/31ABIOMED : Large Multi-Center Study in Japan Finds High Survival Rates with Use o..
07/31ABIOMED : Une importante étude multicentrique au Japon démontre des taux élevés ..
More news
Chart ABIOMED, INC.
Duration : Period :
Abiomed, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABIOMED, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 240,00 $
Last Close Price 316,65 $
Spread / Highest target -1,15%
Spread / Average Target -24,2%
Spread / Lowest Target -52,0%
EPS Revisions
Managers
NameTitle
Michael R. Minogue Chairman, President & Chief Executive Officer
David M. Weber Chief Operating Officer & Senior Vice President
Todd A. Trapp Chief Financial Officer & Vice President
Thorsten Sieß Chief Technology Officer
Seth Bilazarian Vice President-Medical Education & Training
Sector and Competitors
1st jan.Capitalization (M$)
ABIOMED, INC.79.00%13 754
THERMO FISHER SCIENTIFIC27.97%164 454
DANAHER CORPORATION34.27%146 188
INTUITIVE SURGICAL, INC.15.62%79 987
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.89.29%59 540
ILLUMINA, INC.18.67%57 871